HEPATITIS B POLICY PRIORITIES

FEDERAL FUNDING FOR HEPATITIS B AND LIVER CANCER
- Appropriations Advocacy (CDC, NIH)
- The LIVER Act

PREVENTION: HEPATITIS B SCREENING AND VACCINATION
- Expanding Hepatitis B Screening Guidelines
- Increasing Adult Hepatitis B Vaccination

TREATMENT ACCESS
- Ensuring affordability and access to hepatitis B treatments

ENDING HEPATITIS B-RELATED DISCRIMINATION
- Health Care Students and Professionals
- U.S. Military

HEALTH EQUITY
- Health Equity and Accountability Act (HEAA)
Federal Funding for Hepatitis B and Liver Cancer

<table>
<thead>
<tr>
<th>CDC (DVH)</th>
<th>NIH (NIAID, NIDDK, NCI)</th>
<th>WHITE HOUSE ELIMINATION PLAN</th>
</tr>
</thead>
</table>
| CDC’s viral hepatitis prevention and surveillance programs are underfunded and under-prioritized.  
- Estimated cost to implement a comprehensive, national program to eliminate viral hepatitis:  
  - $3.9 billion over 10 years  
  - Current funding level for CDC’s Division of Viral Hepatitis:  
  - $43 million for FY23 | Hepatitis B is preventable and treatable, but there is still no cure for this disease.  
The lack of a cure for hepatitis B costs the U.S. an estimated $4 billion per year in medical costs and has a devastating effect on patients and their families. The hepatitis B research community developed a comprehensive Roadmap for a Cure, along with a professional judgment budget, which recommends increasing NIH funding for hepatitis B research by $232.3 million over 6 years. | The Biden-Harris Administration recently announced a National Plan to Eliminate Hepatitis C. While we applaud this effort, there is a clear missed opportunity in not including any activities or funding towards hepatitis B. Many of the proposed activities are overlapping and could work towards elimination of both hepatitis B and C.  
We recommend that strategies to eliminate hepatitis B are integrated into the new National Plan, including around diagnostics, linkage to care and vaccination, treatment access, and expanding screening and prevention efforts, particularly among high-risk populations. |
| We urge Congress to allocate no less than $150 million in funding for viral hepatitis programs at the CDC. | We urge Congress to increase NIH funding for hepatitis B research by $38.7 million per year. | |

Appropriations Report Language  
Community Project Funding (Congressional Earmarks)
Prevention: Increase Hepatitis B Screening

In the U.S., ~2.4 million people live with hepatitis B and the majority (~65%) are undiagnosed.

The CDC now recommends a one-time universal screening for hepatitis B among adults 18 and older. The previous, risk-based screening guidelines were stigmatizing and ineffective in improving diagnosis rates.

Policy Priorities:
- Ensuring implementation of universal screening guidelines
- Advocate for an update to the U.S Preventive Services Task Force (USPSTF) Recommendation

Call to Action: Eliminating Hepatitis B Virus Through Universal Screening and Vaccination for Adults Ages 19-59
Prevention: Improve Adult Hepatitis B Vaccination Coverage

Only 30% of adults are fully protected against hepatitis B.

The hepatitis B vaccine is universally recommended for all adults aged 19-59, and for those 60 and older who have risk factors.

- Policy Priorities:
  - Increase access to hepatitis B vaccines
  - Eliminate systemic barriers to vaccination

- Advocacy Strategies:
  - Sign-on letters, petitions, surveys (needs of state/local health departments - Section 317 Funding)
  - Public Comment Submissions: federal immunization objectives, considerations, and proposals

- National Adult Hepatitis B Vaccination Awareness Day (April 30th)
  - Toolkit (2023)
Treatment Access

*With no cure for hepatitis B, access to affordable medication is extremely important to preventing significant liver damage or cancer and improving the quality of life of people impacted by hepatitis B.*

**Policy Priorities:**
- Adverse drug tiering
- Cost of hepatitis B medication
- Co-pay accumulators

**Report:** [Health Insurance Costs Impacting People Living with Hepatitis B](https://example.com) (2020)
Ending Hepatitis B-Related Discrimination

Hepatitis B is a protected condition under the Americans with Disabilities Act (2013 DOJ Settlement)

- **Health Care Schools Admission Policies** - Hepatitis B-infected health care providers and students face discrimination, impacting training and/or practice.

- **Department of Defense and U.S. Public Health Service Accession Policies** - People living with hepatitis B who are pursuing careers/serving in the U.S. military and the Commissioned Corps of the USPHS face discriminatory hepatitis B accession policies.

Key Resource: 2012 Updated CDC Recommendations for the Management of Hepatitis B Virus-Infected Health-Care Providers and Students
HEALTH EQUITY AND ACCOUNTABILITY ACT (HEAA)

The Health Equity and Accountability Act (HEAA) = a comprehensive bill to eliminate racial and ethnic health disparities.

HEAA seeks to address the wide spectrum of inequities in health care access, quality, and outcomes including:

- Age
- Disability
- Sex
- Gender
- Immigration status
- Sexual orientation
- Gender identity and expression
- Language
- Socio-economic status
- Historical injustices
- Contemporary injustices

Introduced by the Congressional Tri-Caucus, comprised of CAPAC, CBC and CHC

Title VII, “Addressing High Impact Minority Diseases,” includes a subtitle on viral hepatitis and liver cancer control and prevention

Also includes titles on culturally and linguistically appropriate health care, health workforce diversity, and social determinants of health
Learn More

2022 Advocacy Year in Review

State Advocacy Meetings - This year, we began hosting monthly meetings for Hep B United partners, patients, providers, and other community advocates interested in working on hepatitis B advocacy at the state level to share updates, highlight successful campaigns, exchange resources, get feedback on ideas, discuss challenges/barriers, connect with other advocates, and help identify opportunities for hepatitis B state advocacy across the U.S.

Regional Advocacy Trainings - We collaborated with Hep B United partners in the Mid-Atlantic, South, West, and Northeast to co-host three regional advocacy trainings focused on Getting Started in State Advocacy. These virtual workshops aimed to provide a foundation for organizations and advocates interested in getting more involved in advocacy efforts at the state level.

Viral Hepatitis Elimination Planning - We worked to increase hepatitis B community involvement in state viral hepatitis elimination planning workgroups.

Global Advocacy

Hepatitis B and Hepatitis Delta Global Community Advisory Boards

As pre-clinical and clinical research efforts lead to progress towards development of a functional cure for hepatitis B and effective treatments for hepatitis delta, it is critical to include community perspectives and experiences in this process. This year, the Hepatitis B Foundation created two global Community Advisory Boards (CABs), comprised of 23 CAB members who applied and were selected from 19 countries. The CAB membership reflects the demographics of chronic hepatitis B and D globally, and emphasizes the inclusion of traditionally under-represented communities. Since July, the CABs have been preparing to start meeting with drug and clinical trial developers in 2023, with the goals of integrating community voices, inputs, and recommendations; ensuring patient-centered decision making; and promoting awareness and engagement on drug and clinical trials.

Urging Gavi to Support Hepatitis B Birth Dose

Gavi, the Vaccine Alliance, is an international partnership created to improve access to new and underused vaccines for children living in the world's poorest countries. Previously, Gavi committed to providing support for countries to introduce hepatitis B birth dose, particularly in areas where mother-to-child transmission of hepatitis B is high; however, they have not yet followed through on this. Over the past few months, the Hepatitis B Foundation sent a letter to the Gavi, met virtually with Gavi’s Policy Team and Vaccine Programmes Team, and signed on to an open letter published in The Lancet urging Gavi to start their hepatitis B birth dose campaign. We will continue to pressure Gavi through advocacy.
ANNUAL HEP B UNITED ADVOCACY DAY

+ Remote Opportunities
  • Virtual Advocacy Day and Hill Meetings
  • Virtual Congressional Briefings
ADVOCACY ACTION CENTER

Advocacy
- Overview
- Action Center
- Comments and Letters
- Reports
- Events and Trainings
- Congressional Hepatitis Caucus
- State Advocacy

Action Center

Become a Hep B Advocate! Sign up below to receive the latest news and updates about hepatitis B policy issues, learn about upcoming advocacy events, and be notified of opportunities to take action and show your support for our policy initiatives.

We'll provide resources, information, and tools to help you:
- Communicate effectively with your elected officials
- Educate and engage your community on hepatitis B policy issues
- Recruit and organize other hepatitis B advocates and champions in your community
- Promote and participate in ongoing national, state, and local advocacy efforts

Sign up at: www.hepbunited.org/action
Contact Us

Frank Hood
Associate Director, Policy and Partnerships
frank.hood.hepb.org

Michaela Jackson
Program Director, Prevention Policy
michaela.jackson@hepb.org

Rhea Racho
Program Director, Advocacy and Engagement
rhea.racho@hepb.org